Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston Scientific Ramping Up Internal R&D; Medinol Claims Infringement

This article was originally published in The Gray Sheet

Executive Summary

Boston Scientific's R&D spending is expected to jump roughly 16% to $230 mil. in 2001, reflecting the firm's increased commitment to in-house innovation as opposed to relying primarily on acquisitions to build its product pipeline.

You may also be interested in...



Alternative Stent Supply Agreement Violated By Medinol - BSX Countersuit

Boston Scientific is charging Israeli stent partner Medinol with violating their supply agreement by failing to provide chemical etching services that would benefit an alternative stent line sanctioned by the deal.

Alternative Stent Supply Agreement Violated By Medinol - BSX Countersuit

Boston Scientific is charging Israeli stent partner Medinol with violating their supply agreement by failing to provide chemical etching services that would benefit an alternative stent line sanctioned by the deal.

Boston Scientific Express Stent Potentially Threatened By Medinol Lawsuit

Boston Scientific's strategy to rely on its internally developed Express coronary stent platform as a viable alternative to a troubled relationship with stent partner Medinol may be jeopardized by the Israeli firm's April 5 lawsuit alleging that the Express R&D initiative constituted breach of contract by Boston Scientific.

Related Content

UsernamePublicRestriction

Register

MT014795

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel